A股異動 | 華紡股份(600448.SH)漲停 口罩日產量已達2萬隻
格隆匯2月7日丨華紡股份(600448.SH)臨近午盤收盤前直線拉昇至漲停,現報6元,暫成交1.22億元,最新總市值31.49億元。華紡股份今日在投資者關係互動平台上表示,按照濱州市政府關於做好當前疫情防控工作的部署要求,公司臨時轉產部分產能生產民用口罩,現正在緊密生產中,產量已達日產2萬隻。近期與中國電信合作 5G、AI推動產業升級,工業互聯網是雙方共同明確的企業升級發展的方向和路徑,也是公司創新發展的源生動力之一。上午盤口罩概念股持續上演漲停潮,其中,奧美醫療8連板,泰達股份、振德醫療均6連板。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.